The present disclosure features compounds Formula I or II: or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.
Legal claims defining the scope of protection, as filed with the USPTO.
.-. (canceled)
. (canceled)
. The compound of, or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1.
. (canceled)
. The compound of, or a pharmaceutically acceptable salt thereof, wherein when m is 1, Ris halo, optionally substituted C-Calkyl or optionally substituted C-Ccycloalkyl.
.-. (canceled)
. The compound of, or a pharmaceutically acceptable salt thereof, wherein k is 1 and X is Cl.
. (canceled)
. The compound of, or a pharmaceutically acceptable salt thereof, wherein k is 0.
.-. (canceled)
. The compound of, or a pharmaceutically acceptable salt thereof, wherein at least one of f, h, i, and k is 1.
. The compound ofor a pharmaceutically acceptable salt thereof, wherein each of B, B, B, and Bis, independently, O, ethynyl, optionally substituted C-Cheteroaryl, optionally substituted C-Cheterocyclyl, optionally substituted C-Ccycloalkyl, or optionally substituted C-Caryl.
.-. (canceled)
.-. (canceled)
.-. (canceled)
.-. (canceled)
. A pharmaceutical composition comprising a compound ofand a pharmaceutically acceptable excipient.
. A method of treating a BAF complex-related disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound ofor a pharmaceutical composition.
. (canceled)
. A method of treating a disorder related to a BRG1 loss of function mutation in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of.
. (canceled)
. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of.
. The method of, wherein the cancer is non-small cell lung cancer, colorectal cancer, bladder cancer, cancer of unknown primary, glioma, breast cancer, melanoma, non-melanoma skin cancer, endometrial cancer, esophagogastric cancer, pancreatic cancer, hepatobiliary cancer, soft tissue sarcoma, ovarian cancer, head and neck cancer, renal cell carcinoma, bone cancer, non-Hodgkin lymphoma, small-cell lung cancer, prostate cancer, embryonal tumor, germ cell tumor, cervical cancer, thyroid cancer, salivary gland cancer, gastrointestinal neuroendocrine tumor, uterine sarcoma, gastrointestinal stromal tumor, CNS cancer, thymic tumor, Adrenocortical carcinoma, appendiceal cancer, small bowel cancer, or penile cancer.
.-. (canceled)
Complete technical specification and implementation details from the patent document.
The invention relates to compounds useful for modulating BRG1- or BRM-associated factors (BAF) complexes. In particular, the invention relates to compounds useful for treatment of disorders associated with BAF complex function.
Chromatin regulation is essential for gene expression, and ATP-dependent chromatin remodeling is a mechanism by which such gene expression occurs. The human Switch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex, also known as BAF complex, has two SWI2-like ATPases known as BRG1 (Brahma-related gene-1) and BRM (Brahma). The transcription activator BRG1, also known as ATP-dependent chromatin remodeler SMARCA4, is encoded by the SMARCA4 gene on chromosome 19. BRG1 is overexpressed in some cancer tumors and is needed for cancer cell proliferation. BRM, also known as probable global transcription activator SNF2L2 and/or ATP-dependent chromatin remodeler SMARCA2, is encoded by the SMARCA2 gene on chromosome 9 and has been shown to be essential for tumor cell growth in cells characterized by loss of BRG1 function mutations. Deactivation of BRG and/or BRM results in downstream effects in cells, including cell cycle arrest and tumor suppression.
The present invention features compounds useful for modulating a BAF complex. In some embodiments, the compounds are useful for the treatment of disorders associated with an alteration in a BAF complex, e.g., a disorder associated with an alteration in one or both of the BRG1 and BRM proteins. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating such disorders.
In an aspect, the invention features a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula I or II:
In some embodiments, the compound has the structure of Formula I or II:
In some embodiments, the compound has the structure of Formula I or II:
wherein
A-(B)—(C)—(B)—(B)—(C)—(B)-A, Formula III
B is a degradation moiety;
In some embodiments, the compound has the structure of Formula I-A or II-A:
In some embodiments, the compound has the structure of Formula I-G or II-G:
In some embodiments, the compound has the structure of Formula I-H or II-H:
In some embodiments, m is 0 or 1.
In some embodiments, m is 1.
In some embodiments, Ris halo, optionally substituted C-Calkyl or optionally substituted C-Ccycloalkyl.
In some embodiments, Ris methyl.
In some embodiments, Ris cyclopropane.
In some embodiments, m is 0.
In some embodiments, k is 1.
In some embodiments, X is Cl.
In some embodiments, k is 0.
In some embodiments, the linker is of structure -(L)-, wherein n is 1, 2, or 3, and each Lis independently O, NR, ethynyl, optionally substituted C-Cheterocyclyl, optionally substituted C-Cheteroaryl, optionally substituted C-Caryl, or optionally substituted C-Ccycloalkyl.
In some embodiments, at least one Lis optionally substituted C-Cheterocyclyl. In some embodiments the optionally substituted C-Cheterocyclyl is 4-, 5-, or 6-membered monocyclic heterocyclyl. In some embodiments the 4-, 5-, or 6-membered monocyclic heterocyclyl is:
In some embodiments, the optionally substituted C-Cheterocyclyl is a spirocyclic heterocyclyl. In some embodiments, the spirocyclic heterocyclyl is:
In some embodiments, the optionally substituted C-Cheterocyclyl is a bridged heterocyclyl. In some embodiments the bridged heterocyclyl is:
In some embodiments, the optionally C-Cheterocyclyl is a fused bicyclic heterocyclyl.
In some embodiments, the fused bicyclic heterocyclyl is:
In some embodiments, at least one Lis optionally substituted C-Cheteroaryl. In some embodiments, the linker is -(L)-(optionally substituted C-Cheteroaryl)-(L)-, wherein each q is independently 0 or 1. In some embodiments, the optionally substituted C-Cheteroaryl is a 6-membered monocyclic heteroaryl. In some embodiments, the 6-membered monocyclic heteroaryl is:
In some embodiments, at least one Lis optionally substituted C-Cheteroaryl. In some embodiments, the linker is:
In some embodiments, at least one Lis optionally substituted C-Caryl. In some embodiments, the optionally substituted C-Caryl is a 6-membered monocyclic aryl. In some embodiments, the 6-membered monocyclic aryl is optionally substituted phenyl.
In some embodiments, at least one Lis optionally substituted C-Ccycloalkyl. In some embodiments, the optionally substituted C-Ccycloalkyl is a monocyclic cycloalkyl. In some embodiments, the 6-membered monocyclic cycloalkyl is:
In some embodiments, the optionally substituted C-Ccycloalkyl is a bridged cycloalkyl. In some embodiments, the bridged cycloalkyl is:
In some embodiments, at least one Lis ethynyl.
In some embodiments, one and only one Lis O. In some embodiments, one and only one Lis NR. In some embodiments, Ris optionally substituted C-Calkyl. In some embodiments, Ris H.
In some embodiments, the linker is of the following structure:
A-(B)—(B)—(B)—(B)-A,
Unknown
October 2, 2025
Browse 5M+ US patents with plain-English claim translations and AI-generated analysis.